Catalent Global, cGMP Micronizing and Milling for the Pharmaceutical Industry

Support new drug proposals

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products.

With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents.

Catalent has helped innovators ranging from small start-ups to Fortune 5 Pharma companies by optimizing and manufacturing thousands of pharmaceutical, biologic, consumer health and beauty products.

Contact us today to see how we can help you get your product to market faster.

Development expertise

With extensive early phase development expertise in analytics, biologics, pre-formulation and formulation, we can help you achieve faster more efficient development timelines to produce better products.

  • In pharmaceuticals we provide expert guidance, pre-screen solubility assessments for drugability, a best-in class API optimization platform, and a wide array of the most up-to-date bioavailability enhancement tools, including particle size reduction, spray drying, hot melt extrusion, and lipid based drug delivery systems.
  • In biologics, we help accelerate you to clinic and beyond with GPEx® technology to generate stable, high-performance cell lines.
  • In consumer health, we help you deliver innovative products backed by an extensive product library to help get you on the market faster.

Advanced Delivery Technologies

Our innovative dose forms and advanced manufacturing technologies can help you to create better products and therapeutic outcomes to improve the lives of patients and consumers. Our superior enabling formulation technologies can help you meet your target product profile, improve value, and achieve better outcomes, including:

  • RP Scherer Softgel Delivery Technologies
  • Zydis® Fast Dissolve Delivery Technology
  • Advasept® glass-free injectable technology
  • SMARTag® antibody drug conjugate technology

Getting product to the market

Whether it’s managing your clinical supply needs or commercially manufacturing your products, we have a solution for you.

  • Our clinical supply services can help you manage your local, regional, or global studies, including special handling capabilities and comparator sourcing services.
  • Our flexible manufacturing solutions can help you scale up and get to market with tailored solutions and special handling capabilities, all backed by discipline, rigor, and rhythm that has resulted in a reliable global network that will supply your product to the highest quality standards on time.

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

Catalent to Manufacture Opiod Discontinuation Treatment Iofexidine

Catalent Pharma Solutions has announced it has entered an exclusive agreement with US WorldMeds for the commercial manufacture of lofexidine, an investigational drug under development to mitigate symptoms associated with opioid withdrawal and facilitate completion of opioid discontinuation treatment.

Product and Services
White Papers

AsiaPacific Region Studies, Common Clinical Supply Challenges

The number of clinical trials in the Asia-Pacific (APAC) region is growing as sponsors tap into expanding pharmaceutical market.

Address
Catalent

14 Schoolhouse Road

Somerset, NJ 08873

United States of America

+1 732 537 6200 +1 610 251 7400 www.catalent.com Development Delivery Supply Catalent Biologics Consumer Health Animal Health

Catalent Images

Press Release

6 September 2017

Catalent Pharma Solutions has announced it has entered an exclusive agreement with US WorldMeds for the commercial manufacture of lofexidine, an investigational drug under development to mitigate symptoms associated with opioid withdrawal and facilitate completion of opioid discontinuation treatment.

Read more
21 July 2017

The Catalent Applied Drug Delivery Institute has announced it has entered a collaboration with the Department of Pharmacy Practice at Rutgers University to identify and address the specific challenges of paediatric formulation and drug delivery.

Read more
18 July 2017

Catalent Pharma Solutions has announced it has broadened the scope of its multi-award winning OptiForm® Solution Suite platform to provide an efficient and seamless path from late-stage discovery to Phase I clinical trials.

Read more
5 April 2017

Catalent Pharma Solutions has announced it has completed an expansion project at its Kansas City facility to significantly increase controlled-temperature storage capabilities for its clinical supply business.

Read more
17 February 2017

Catalent has announced it has completed the acquisition of Accucaps Industries, a Canada-based developer and manufacturer of Over-the-Counter (OTC), high-potency, and conventional pharmaceutical softgels. Financial details of the transaction have not been disclosed.

Read more
2 February 2017

Catalent Pharma's new state-of-the-art biologics manufacturing facility in Madison utilises single-use systems and offers both flexibility and scale to support your growth.

Read more
23 January 2017

Catalent Pharma Solutions (Stand A80) has announced it will be showcasing its specialised expertise and capabilities in aseptic filling and packaging and patient-centric dose form technologies at the upcoming Pharmapack Europe event.

Read more
29 November 2016

Global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products Catalent has announced that the company has agreed to acquire Accucaps Industries, the Canada-based developer and manufacturer of over-the-counter (OTC), high-potency, and conventional pharmaceutical softgels.

Read more
5 October 2016

Catalent has announced that Triphase Accelerator Corporation will obtain worldwide rights to further develop its proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent's wholly owned subsidiary Redwood Bioscience using its SMARTag™ technology platform.

Read more
19 July 2016

Catalent has announced it will build a new, flexible GMP space at its Singapore facility with an investment of $4.6M.

Read more
1 February 2016

Catalent Pharma Solutions has announced that it will invest $4.6m to further expand its Singapore clinical supply facility by building new flexible GMP space for secondary packaging, doubling its ambient storage space, and quadrupling cold storage capacity.

Read more
27 January 2016

Catalent Pharma Solutions has announced that Cerenis Therapeutics has advanced its leading clinical candidate, CER-001, into Phase III clinical studies across Europe and North America.

Read more

Regional Offices

Catalent

14 Schoolhouse Road

Somerset, NJ 08873

United States of America

+1 732 537 6200 +1 610 251 7400 www.catalent.com Development Delivery Supply Catalent Biologics Consumer Health Animal Health
Catalent

2125 Ambassador Drive

Windsor, N9C 3R5

Ontario

United States of America

+1 800 665 7210
Catalent

Avenida Jerome Case, 1277,

Sorocaba, SP, 18087-220

Brazil

+55 15 3235 3513
Catalent

399 Chengnan Rd

Haining,

Zhejiang 314408

China

+86 573 8741 2028
Catalent

1656 Kurami,

Kakegawa.shi,

Shizuoka 436-0341,

Japan

+81 537 29 1131

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.